Tricuspid Regurgitation and 3-Year Mortality After Transseptal Mitral Valve-in-Valve Replacement

There is a paucity of data on the impact of transcatheter mitral valve interventions on tricuspid regurgitation (TR).

This study aimed to assess the impact of preprocedural TR, residual TR at 30 days, and the associated change in TR severity after transseptal mitral valve-in-valve (MViV) replacement on 3-year mortality.

The Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry was used to extract data for all patients (n = 5,971) undergoing MViV from 2015 to 2024 at 513 sites. Propensity score matching was used to compare the impact of severe or greater TR on 3-year all-cause mortality.

Of the 4,938 patients who met the inclusion criteria, 1,039 (21.0%) had severe or greater TR at baseline. Preprocedural severe or greater TR was associated with significantly higher 3-year mortality compared with moderate and mild or less TR (39.4% vs 31.3% vs 27.7%; P = 0.004). Among patients with severe or greater TR, at least 1-grade improvement was noted in 68.1% at 30 days after MViV. In the 30-day landmark analysis, 3-year mortality was significantly higher in the group with residual severe or greater TR compared with moderate or less TR (43.2% vs 30.7%; P = 0.04). Improvement in TR grade from baseline to 30 days was associated with lower mortality compared with unchanged or worsened TR.

Preprocedural severe or greater TR, 30-day residual severe or greater TR, and unchanged or worsened TR after transseptal MViV were associated with a significantly increased risk for 3-year all-cause mortality. These findings underscore the negative impact of severe TR in multivalvular disease and identify a high-risk group for early intervention with transcatheter tricuspid therapies.